科創新源(300731.SZ):2019年度計提壞賬準備、存貨跌價準備和商譽減值準備合計1370.45萬元
格隆匯4月8日丨科創新源(300731.SZ)公佈,依據《企業會計準則第8號——資產減值》及公司會計政策、會計估計的相關規定,本着謹慎性原則,公司對合並報表範圍內截至2019年12月31日的應收賬款、其他應收款、存貨和商譽進行了減值測試。公司對2019年度計提的壞賬準備、存貨跌價準備和商譽減值準備合計1370.45萬元。
2019年度,公司根據《企業會計準則》以及公司會計政策、會計估計的相關規定計提資產減值準備1370.45萬元,對利潤總額的影響為1370.45萬元,此次計提資產減值準備已經公證天業會計師事務所(特殊普通合夥)審計確認。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.